These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 30903517)
1. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Provencio M; Carcereny E; Artal Á Clin Transl Oncol; 2019 Nov; 21(11):1464-1471. PubMed ID: 30903517 [TBL] [Abstract][Full Text] [Related]
2. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Sgambato A; Casaluce F; Gridelli C Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698 [TBL] [Abstract][Full Text] [Related]
3. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934 [TBL] [Abstract][Full Text] [Related]
4. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990 [TBL] [Abstract][Full Text] [Related]
5. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy]. Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Yang J; Chen J; Wei J; Liu X; Cho WC Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430 [TBL] [Abstract][Full Text] [Related]
7. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833 [TBL] [Abstract][Full Text] [Related]
8. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Fucà G; Galli G; Poggi M; Lo Russo G; Proto C; Imbimbo M; Vitali M; Ganzinelli M; Lanti C; Molino G; Stangoni F; Zilembo N; de Braud F; Garassino MC; Signorelli D Target Oncol; 2018 Dec; 13(6):795-800. PubMed ID: 30306460 [TBL] [Abstract][Full Text] [Related]
10. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in Lung Cancer: From a Minor God to the Olympus. Russo A; McCusker MG; Scilla KA; Arensmeyer KE; Mehra R; Adamo V; Rolfo C Adv Exp Med Biol; 2020; 1244():69-92. PubMed ID: 32301011 [TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs? Attili I; Passaro A; Pavan A; Conte P; De Marinis F; Bonanno L Crit Rev Oncol Hematol; 2017 Nov; 119():30-39. PubMed ID: 29065983 [TBL] [Abstract][Full Text] [Related]
14. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. Dong J; Li B; Zhou Q; Huang D J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922 [TBL] [Abstract][Full Text] [Related]
16. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Moon EK; Langer CJ; Albelda SM Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. Reck M Immunotherapy; 2018 Feb; 10(2):93-105. PubMed ID: 29145737 [TBL] [Abstract][Full Text] [Related]
18. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Garon EB Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528 [TBL] [Abstract][Full Text] [Related]
20. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer]. Wang S; Li J Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]